Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

Fig. 1

Progression-free survival (PFS) in the Asian and non-Asian populations (a), and by first-line treatment cohorts in the Asian and non-Asian populations for (b) sunitinib, (c) other anti-VEGF agents, and (d) cytokines. CI=confidence interval; K-M=Kaplan-Meier; NE=not estimable; PFS=progression-free survival; VEGF=vascular endothelial growth factor

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us